Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.

Jeannine A. Villella,Michelle K. Wilson,Neil Lorne Berinstein,Mohan Karkada,Tara Quinton,Marcus O. Butler,Stephanie Lheureux,Victoria Mandilaras,Neesha C. Dhani,Genevieve Weir,Lisa MacDonald,Rita Nigam,Marianne Stanford,Marc Mansour,Amit M. Oza

Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.

2016

Jeannine A. Villella
Michelle K. Wilson
Neil Lorne Berinstein
Mohan Karkada
Tara Quinton
Marcus O. Butler
Stephanie Lheureux
Victoria Mandilaras
Neesha C. Dhani
Genevieve Weir
Lisa MacDonald
Rita Nigam
Marianne Stanford
Marc Mansour
Amit M. Oza

e14577Background: Survivin is an important protein that regulates apoptosis, proliferation, and angiogenesis of tumors. Increased expression of survivin in various tumors correlates with progressio...

Keywords:

DPX-Survivac
Fallopian tube
Treatment Schedule
Oncology
Peritoneal cancer
Pathology
Immunotherapy
Internal medicine
Medicine
Angiogenesis
Apoptosis
Cancer research
combination immunotherapy
Survivin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations